Please assess the completion status of the following clinical trial:

Trial Title: A Multicenter Phase 3 Study of Interferon-beta-1a for the Treatment of Chronic Hepatitis C in Asian Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 18 and 65 years~* Have an elevated serum alanine aminotransferase (ALT) between 1.5 and 10 times the upper limit of normal~* Had adequate bone marrow reserve and organ function~* Are not pregnant and are willing to use contraception, if, of childbearing potential~* Are willing and able to comply with the protocol and to give written informed consent~* Other protocol defined inclusion criteria may apply~Exclusion Criteria:~* Clinical evidence of liver cirrhosis or a diagnosis of definite cirrhosis on liver biopsy~* History of liver failure, severe retinopathy, immunologically mediated disease, cancer or epilepsy with a history of inadequately controlled seizures~* Any cause for the liver disease other than chronic hepatitis C~* Evidence of chronic renal impairment, liver cancer, unstable psychiatric disorder, known or ongoing alcohol or drug abuse~* Positive test at screening for Hepatitis B surface antigen, immunoglobulin M Hepatitis B core antibody and human immunodeficiency virus antibody~* Previous systemic treatment for Hepatitis C with an interferon or ribavirin~* Presence of systemic disease that might interfere with subject safety, compliance or evaluation~* Known allergies to acetaminophen, human serum albumin or mannitol;~* Glucocorticosteroids or other immunosuppressive drugs taken within 28 days of starting treatment~* Bearing organ transplants (except cornea)~* Other protocol defined exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Interferon-beta-1a (Type: EXPERIMENTAL): None
- Ribavarin plus interferon-beta-1a (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).